IGF-1 LR3
Insulin-like Growth Factor-1 Long R3 • Also called IGF1-LR3, IGF 1 LR3, Long R3 IGF-1
IGF-1 LR3 remains a staple search term in bodybuilding and biohacking markets, but FDA has treated compounded products using it as lacking a qualifying 503A basis.
Current status
Restricted
Growth- and recovery-related interest, with current federal compounding constraints still in play.
FDA category
Not on 503A bulks list
Can pharmacies compound this?
No
Reclassification expected?
Unclear
The current issue is not a near-term review queue. FDA has already described compounded IGF1-LR3 products as ineligible for the usual 503A exemptions.
Primary Use
Growth- and recovery-related interest
Also searched as
IGF1-LR3, IGF 1 LR3, Long R3 IGF-1
Regulatory Timeline
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Apr 1, 2020
Current status signal recorded: FDA warning-letter posture says it is not the subject of an applicable USP or NF monograph, is not a component of an FDA-approved human drug, and does not appear on the 503A bulks list..
Get notified...
Get notified when IGF-1 LR3 status changes
State-specific notes
Ohio
High-risk performance peptides tend to disappear quickly from compliant sourcing channels.